Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial
- 1 July 2021
- journal article
- research article
- Published by Elsevier in Diabetes & Metabolism
- Vol. 47 (4) , 101190
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- The Gap between Estimated Incidence of End-Stage Renal Disease and Use of TherapyPLOS ONE, 2013
- Aldosterone Blunts Tubuloglomerular Feedback by Activating Macula Densa Mineralocorticoid ReceptorsHypertension, 2012
- Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney diseaseKidney International, 2011
- Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trialEuropean Heart Journal, 2011
- Proteinuria in DiabetesJournal of the American Society of Nephrology, 2010
- Validation of the mobil-O-Graph: 24 h-blood pressure measurement deviceBlood Pressure Monitoring, 2010
- Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials?Statistics in Medicine, 2009
- Enhanced Aldosterone Signaling in the Early Nephropathy of Rats with Metabolic SyndromeJournal of the American Society of Nephrology, 2006
- Mineralocorticoid and Angiotensin Receptor Antagonism During HyperaldosteronemiaHypertension, 2002
- “WATER DIURESIS” PRODUCED DURING RECUMBENCY BY THE INTRAVENOUS INFUSION OF ISOTONIC SALINE SOLUTION 1Journal of Clinical Investigation, 1951